Loading...
•
Mar 31, 2022
Verrica Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
Verrica Pharmaceuticals reported license revenues of $0.4 million and a net loss of $8.5 million, or $0.31 per share, for the first quarter of 2022. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $61.9 million as of March 31, 2022.
Verrica achieved commercial readiness and entered the final stage of pre-launch operations for VP-102.
The PDUFA date for VP-102 is approaching, potentially becoming the first FDA-approved treatment for molluscum.
The first patient was dosed in the Phase 2 trial of LTX-315 in basal cell carcinoma.
Verrica believes its existing cash will be sufficient to support planned operations into the third quarter of 2022.
Forward Guidance
Verrica believes that its existing cash, cash equivalents and marketable securities as of March 31, 2022, will be sufficient to support planned operations into the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...